Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

This study is a phase 1/3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma

Participants needed: 486
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: CelltrionUpdated: Aug 15, 2025Locations: 1
Eligibility criteria

Male or female with 18 years of age or older. [+4]

Patient has received daratumumab or any other drug specifically targeting CD38 p... [+2]

Read more
Status: Recruiting

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.

Participants needed: 171
Trial details
Phase: Phase 3Age: 19+Biological sex: AllType: InterventionalSponsor: CelltrionUpdated: Aug 11, 2025Locations: 1
Eligibility criteria

Adults at the time of signing the Informed Consent Form (ICF) [+2]

Diagnosed with other types of diabetes than T2DM [+2]

Read more
Status: Recruiting

A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.

Participants needed: 606
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: CelltrionUpdated: Apr 23, 2025Locations: 1
Eligibility criteria

Stage IV, non squamous NSCLC [+2]

Have predominantly squamous cell histology NSCLC. [+1]

Read more
Status: Recruiting

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.

Participants needed: 512
Trial details
Phase: Phase 3Age: 18-55Biological sex: AllType: InterventionalSponsor: CelltrionUpdated: May 22, 2024Locations: 1
Eligibility criteria

Patient diagnosed as multiple sclerosis (MS) in accordance with the revised McDo... [+3]

Patient diagnosed with primary or secondary progressive MS. [+5]

Read more